In a land­mark first, Chi­nese sci­en­tist claims birth of ge­net­i­cal­ly mod­i­fied ba­bies — and all hell breaks loose

A Chi­nese re­searcher is claim­ing that he cre­at­ed the first-ever ge­net­i­cal­ly edit­ed ba­bies us­ing CRISPR/Cas9 tools that have now be­come a com­mon fea­ture in labs around the world. And the news trig­gered a tem­pest in sci­en­tif­ic cir­cles the world over as re­searchers who have been us­ing gene-edit­ing tech to re­fine plants and forge new ther­a­pies try to puz­zle out the stun­ning —if true — de­vel­op­ment fea­tured on YouTube.

Sev­er­al ex­perts — in­clud­ing co-in­ven­tor Feng Zhang — crit­i­cized the ex­per­i­ment, rais­ing po­ten­tial safe­ty is­sues that could arise as a re­sult of the ge­net­ic tin­ker­ing. And Rice Uni­ver­si­ty, where a pro­fes­sor was re­port­ed­ly in­volved, is in­ves­ti­gat­ing.

The sci­en­tist who claimed cred­it for the work, though, of­fered a sun­ny per­spec­tive on YouTube.

“Two beau­ti­ful Chi­nese girls named Lu­lu and Nana came cry­ing in­to the world as healthy as any oth­er ba­bies a few weeks ago,” said Shen­zhen-based re­searcher Jiankui He in the YouTube video and WeChat post. But this was no av­er­age birth. The re­searcher’s un­ver­i­fied claim is that the twins’ em­bryos have been ge­net­i­cal­ly en­gi­neered with CRISPR to de­com­mis­sion CCR5, a gene used by HIV as a back door in­to a cell.

Ahead of an in­ter­na­tion­al con­fer­ence on gene edit­ing ex­pect­ed to com­mence on Tues­day in Hong Kong, He said he had al­tered em­bryos for sev­en cou­ples dur­ing fer­til­i­ty treat­ments, with one preg­nan­cy re­sult­ing thus far. But the le­git­i­ma­cy of the project is be­ing in­ves­ti­gat­ed. The South­ern Uni­ver­si­ty of Sci­ence and Tech­nol­o­gy in Shen­zhen, with which He is af­fil­i­at­ed, is­sued a state­ment say­ing it was “deeply shocked” and un­aware of his re­search project which they con­sid­er a “se­ri­ous vi­o­la­tion of aca­d­e­m­ic ethics and stan­dards.” The uni­ver­si­ty added He has been on leave with­out pay since Feb­ru­ary.

He has claimed his aim was not to cure or pre­vent an in­her­it­ed dis­ease, but to con­fer a trait that is nat­u­ral­ly com­mon in parts of North­ern Eu­rope — an abil­i­ty to re­sist an HIV in­fec­tion from the AIDS virus. But the choice to ed­it this CCR5 gene, the block­ade of which may al­so be ef­fec­tive in thwart­ing cholera and small­pox, im­me­di­ate­ly trig­gered an on­line up­roar over the use of CRISPR to al­ter DNA in a way that could be passed down for gen­er­a­tions to come.

MIT Tech­nol­o­gy Re­view’s An­to­nio Re­gal­a­do point­ed out this could be par­tic­u­lar­ly con­tro­ver­sial be­cause there are eas­i­er and cheap­er ways to pre­vent HIV in­fec­tion, or in­deed sup­press it. Edit­ing em­bryos dur­ing IVF will al­so be ex­pen­sive and in­volve tech­nol­o­gy out of reach for poor­er pock­ets of the world where HIV is ubiq­ui­tous.

Some are al­so sug­gest­ing the sto­ry rais­es oth­er thorny ques­tions. Im­pe­r­i­al Col­lege in­ves­ti­ga­tor Tom El­lis not­ed:

Al­though there is sci­en­tif­ic con­sen­sus that gene edit­ing should not be em­ployed to make “de­sign­er ba­bies” en­dowed with en­hanced phys­i­cal fea­tures or in­tel­lec­tu­al traits, the ju­ry is out on to what de­gree sci­ence should in­ter­fere with na­ture to pre­vent, treat or cure dis­ease.

In ad­di­tion to Chi­na, lab­o­ra­to­ry re­search is un­der­way in Swe­den and the UK, in­ves­ti­gat­ing the po­ten­tial of gene-edit­ing in hu­man em­bryos. But in the Unit­ed States it’s a po­lit­i­cal­ly charged propo­si­tion that has won the nar­row en­dorse­ment of the Na­tion­al Acad­e­my of Sci­ences, which last year rec­om­mend­ed that germ-line mod­i­fi­ca­tion of hu­mans was jus­ti­fied in some cir­cum­stances, such as pre­vent­ing the birth of chil­dren with se­ri­ous dis­eases. This rec­om­men­da­tion will like­ly fall on deaf ears, as sec­tions of the pub­lic ve­he­ment­ly op­pose such in­ter­fer­ence on re­li­gious grounds. In fact such mod­i­fi­ca­tions are prac­ti­cal­ly out of the ques­tion — with laws in place pro­hibit­ing the FDA from even con­sid­er­ing pro­pos­als to cre­ate ge­net­i­cal­ly-edit­ed off­spring.

The promise of CRISPR/Cas9 edit­ing has long been her­ald­ed. How­ev­er, ex­per­i­men­ta­tion with the pro­ce­dure has yield­ed sig­nif­i­cant safe­ty con­cerns. Da­ta pre­sent­ed ear­li­er this year sug­gest that the tool, which is es­sen­tial­ly a pair of mol­e­c­u­lar scis­sors, may in­ad­ver­tent­ly in­crease can­cer risk in some cells, or in­tro­duce ac­ci­den­tal mu­ta­tions — is­sues that could ham­per the de­vel­op­ment of gene-edit­ing ther­a­pies cham­pi­oned by com­pa­nies such as CRISPR Ther­a­peu­tics $CR­SP, Ed­i­tas Med­i­cine $ED­IT and In­tel­lia Ther­a­peu­tics $NT­LA.

“The ge­net­ic edit­ing of a speck-size hu­man em­bryo car­ries sig­nif­i­cant risks, in­clud­ing the risks of in­tro­duc­ing un­want­ed mu­ta­tions or yield­ing a ba­by whose body is com­posed of some edit­ed and some unedit­ed cells. Da­ta on the Chi­nese tri­al site in­di­cate that one of the fe­tus­es is a ‘mo­sa­ic’ of cells that had been edit­ed in dif­fer­ent ways,” Re­gal­a­do un­der­scored in his ar­ti­cle.

He’s project in­volved cou­ples in which the men had HIV but the women did not, and the goal was to pre­vent their chil­dren from suf­fer­ing the same fate.

Ac­cord­ing to the AP re­port, He said that in one twin, both copies of the in­tend­ed gene had been al­tered, while in the oth­er twin, just one copy had been dis­abled — and that there was no ev­i­dence of harm to any oth­er genes. Hu­mans with one copy of the gene can still be in­fect­ed with HIV.

The edit­ing oc­curred dur­ing IVF — first, the sperm was sep­a­rat­ed from the se­men where HIV is known to linger. Then, a sin­gle sperm was placed in­to a soli­tary egg to cre­ate an em­bryo when the gene-edit­ing tool was em­ployed. Cou­ples re­cruit­ed to the study were giv­en free fer­til­i­ty treat­ment in re­turn for their par­tic­i­pa­tion and of­fered the choice to use ei­ther edit­ed or non-edit­ed em­bryos for preg­nan­cy at­tempts. Over­all, 16 of 22 em­bryos were edit­ed, and 11 em­bryos were used in 6 im­plant at­tempts be­fore the twin preg­nan­cy was re­al­ized, He told the AP.

He, who is al­so a founder of a DNA se­quenc­ing com­pa­ny Di­rect Ge­nomics, ob­tained in­formed con­sent from par­tic­i­pants call­ing the study an “AIDS vac­cine de­vel­op­ment project.” How­ev­er, in his ap­pli­ca­tion form seek­ing eth­i­cal ap­proval, he dubbed it a CCR5 gene edit­ing project.

Press re­ports tied his work to Rice Uni­ver­si­ty’s Michael Deem, who now will have to an­swer for what, ex­act­ly, they did. Rice Uni­ver­si­ty was quick to launch its own probe. They not­ed:

Re­cent press re­ports de­scribe a case of ge­nom­ic edit­ing of hu­man em­bryos in Chi­na. These re­ports in­clude a de­scrip­tion of in­volve­ment by Dr. Michael Deem, a pro­fes­sor of bio­engi­neer­ing at Rice Uni­ver­si­ty. This re­search rais­es trou­bling sci­en­tif­ic, le­gal and eth­i­cal ques­tions.  Rice of­fers the fol­low­ing state­ment:

  1. Rice had no knowl­edge of this work.

  2. To Rice’s knowl­edge, none of the clin­i­cal work was per­formed in the Unit­ed States.

  3. Re­gard­less of where it was con­duct­ed, this work as de­scribed in press re­ports, vi­o­lates sci­en­tif­ic con­duct guide­lines and is in­con­sis­tent with eth­i­cal norms of the sci­en­tif­ic com­mu­ni­ty and Rice Uni­ver­si­ty.

  4. We have be­gun a full in­ves­ti­ga­tion of Dr. Deem’s in­volve­ment in this re­search.

And two founders of CRISPR were al­so quick to note their own prob­lems with the Chi­na em­bryo project.

The Broad In­sti­tute’s Feng Zhang, a co-in­ven­tor of the tech­nol­o­gy, had this to say:

Al­though I ap­pre­ci­ate the glob­al threat posed by HIV, at this stage, the risks of edit­ing em­bryos to knock out CCR5 seem to out­weigh the po­ten­tial ben­e­fits, not to men­tion that knock­ing out of CCR5 will like­ly ren­der a per­son much more sus­cep­ti­ble for West Nile Virus. Just as im­por­tant, there are al­ready com­mon and high­ly-ef­fec­tive meth­ods to pre­vent trans­mis­sion of HIV from a par­ent to an un­born child.

Giv­en the cur­rent ear­ly state of genome edit­ing tech­nol­o­gy, I’m in fa­vor of a mora­to­ri­um on im­plan­ta­tion of edit­ed em­bryos, which seems to be the in­ten­tion of the CCR5 tri­al, un­til we have come up with a thought­ful set of safe­ty re­quire­ments first.

Not on­ly do I see this as risky, but I am al­so deeply con­cerned about the lack of trans­paren­cy sur­round­ing this tri­al.


Im­age: Jiankui He. THE HE LAB via YOUTUBE

As­traZeneca trum­pets the 'mo­men­tous' da­ta they found for Tagris­so in an ad­ju­vant set­ting for NSCLC — but many of the ex­perts aren’t cheer­ing along

AstraZeneca is rolling out the big guns this evening to provide a salute to their ADAURA data on Tagrisso at ASCO.

Cancer R&D chief José Baselga calls the disease-free survival data for their drug in an adjuvant setting of early stage, epidermal growth factor receptor-mutated NSCLC patients following surgery “momentous.” Roy Herbst, the principal investigator out of Yale, calls it “transformative.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Pablo Legorreta, founder and CEO of Royalty Pharma AG, speaks at the annual Milken Institute Global Conference in Beverly Hills, California (Patrick T. Fallon/Bloomberg via Getty Images)

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few se­crets along the way

Pablo Legorreta is one of the most influential players in biopharma you likely never heard of.

Over the last 24 years, Legorreta’s Royalty Pharma group has become, by its own reckoning, the biggest buyer of drug royalties in the world. The CEO and founder has bought up a stake in a lengthy list of the world’s biggest drug franchises, spending $18 billion in the process — $2.2 billion last year alone. And he’s become one of the best-paid execs in the industry, reaping $28 million from the cash flow last year while reserving 20% of the cash flow, less expenses, for himself.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

Women expel on average about 2 to 3 tablespoons of blood during their time of the month. But with uterine fibroids, heavy bleeding is typical — a third of a cup or more. Drugmakers have been working on oral therapies to try and stem the flow, and as expected, AbbVie and their partners at Neurocrine Biosciences are the first to make it across the finish line.

Known chemically as elagolix, the drug is already approved as a treatment for endometriosis under the brand name Orilissa. It targets the GnRH receptor to decrease the production of estrogen and progesterone.

As tislelizum­ab gains trac­tion in Chi­na, BeiGene pulls the cur­tain on NSCLC da­ta sup­port­ing the PD-1 drug

In a world now brimming with checkpoint inhibitors, companies often struggle to make a mark given a raft of therapies have already captured a considerable portion of the vast oncology market.

BeiGene’s tislelizumab was the fourth PD(L)-1 inhibitor to secure approval in China — and as it works on expanding its share the company has put out detailed data on the use of the drug in certain patients with lung cancer.

Fabrice Chouraqui, Cellarity CEO-partner (LinkedIn)

Drug de­vel­op­er, Big Phar­ma com­mer­cial ex­ec, now an up­start biotech chief — Fab­rice Chouraqui is ready to try some­thing new as a ‘CEO-part­ner’ at Flag­ship

Fabrice Chouraqui’s career has taken some big twists along his life journey. He got his PharmD at Université Paris Descartes and jumped into the drug development game for a bit. Then he took a sharp turn and went back to school to get his MBA at Insead before returning to pharma on the commercial side.

Twenty years later, after steadily rising through the ranks and journeying the globe to nab a top job as president of US pharma for the Basel-based Novartis, Chouraqui exited in another career switch. And now he’s headed into a hybrid position as a CEO-partner at Flagship, where he’ll take a shot at leading Cellarity — one of the VC’s latest paradigm-changing companies of the groundbreaking model that aspires to deliver a new platform to the world of drug R&D.

David Chang, Allogene CEO (Jeff Rumans)

Head­ed to PhII: Al­lo­gene CEO David Chang com­pletes a pos­i­tive ear­ly snap­shot of their off-the-shelf CAR-T pi­o­neer

Allogene CEO David Chang has completed the upbeat first portrait of the biotech’s off-the-shelf CAR-T contender ALLO-501 at virtual ASCO today, keeping all eyes on a drug that will now try to go on to replace the first-wave personalized pioneers he helped create.

The overall response rate outlined in Allogene’s abstract for treatment-resistant patients with non-Hodgkin lymphoma slipped a little from the leadup, but if you narrow the patient profile to treatment-naïve patients — removing the 3 who had previous CAR-T therapy who didn’t respond, leaving 16 — the ORR lands at 75% with a 44% complete response rate. And 9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

In the middle of Sanofi’s multi-pronged race to develop a Covid-19 vaccine, David Loew, the head of their sprawling vaccines unit, is leaving – part of the final flurry of moves in the French giant’ months-long corporate shuffle that will give them new-look leadership under new CEO Paul Hudson.

The company also said today that Alan Main, the head of their consumer healthcare unit, is out, and they named 4 executives to fill new or newly vacated positions, 3 of whom come from both outside both Sanofi and from Pharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Dan O'Day, Gilead CEO (Andrew Harnik, AP Images)

UP­DAT­ED: Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Gilead CEO Dan O’Day has brokered his way to a PD-1 and lined up a front row seat in the TIGIT arena, inking a deal worth close to $2 billion to align the big biotech closely with Terry Rosen’s Arcus. And $375 million of that comes upfront, with cash for the buy-in plus equity, along with $400 million for R&D and $1.22 billion in reserve to cover opt-in payments and milestones..

Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab. O’Day also has first dibs on TIGIT and 2 other leading programs, agreeing to an opt-in fee ranging from $200 million to $275 million on each. There’s $500 million in potential TIGIT milestones on US regulatory events — likely capped by an approval — if Gilead partners on it and the stars align on the data. And there’s another $150 million opt-in payments for the rest of the Arcus pipeline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.

Paul Hudson, Sanofi CEO (Getty Images)

Sanofi CEO Paul Hud­son has $23B burn­ing a hole in his pock­et. And here are some hints on how he plans to spend that

Sanofi has reaped $11.1 billion after selling off a big chunk of its Regeneron stock at $515 a share. And now everyone on the M&A side of the business is focused on how CEO Paul Hudson plans to spend it.

After getting stung in France for some awkward politicking — suggesting the US was in the front of the line for Sanofi’s vaccines given American financial support for their work, versus little help from European powers — Hudson now has the much more popular task of managing a major cash cache to pull off something in the order of a big bolt-on. Or two.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 81,800+ biopharma pros reading Endpoints daily — and it's free.